Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics

被引:61
作者
Jani, Marton [1 ]
Ambrus, Csilla [1 ]
Magnan, Remi [1 ]
Jakab, Katalin Tauberne [1 ]
Beery, Erzsebet [1 ]
Zolnerciks, Joseph K. [1 ]
Krajcsi, Peter [1 ]
机构
[1] Solvo Biotechnol, Szeged, Hungary
关键词
BCRP; ABCG2; ADMETox; Physiology; Biomarker; Pharmacokinetics; Pharmacogenomics; Drug Transporter; Transporter assay; Multidrug resistance; CANCER-RESISTANCE-PROTEIN; BLOOD-BRAIN-BARRIER; BINDING CASSETTE TRANSPORTER; SIDE-POPULATION CELLS; SINGLE-NUCLEOTIDE POLYMORPHISMS; P-GLYCOPROTEIN ABCB1; TARGETED ABSOLUTE PROTEOMICS; HEMATOPOIETIC STEM-CELLS; ABCG2 C421A POLYMORPHISM; SERUM URIC-ACID;
D O I
10.1007/s00204-014-1224-8
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The discovery and characterization of breast cancer resistance protein (BCRP) as an efflux transporter conferring multidrug resistance has set off a remarkable trajectory in the understanding of its role in physiology and disease. While the relevance in drug resistance and general pharmacokinetic properties quickly became apparent, the lack of a characteristic phenotype in genetically impaired animals and humans cast doubt on the physiological importance of this ATP-binding cassette family member, similarly to fellow multidrug transporters, despite well-known endogenous substrates. Later, high-performance genetic analyses and fine resolution tissue expression data forayed into unexpected territories concerning BCRP relevance, and ultimately, the rise of quantitative proteomics allows putting observed interactions into absolute frameworks for modeling and insight into interindividual and species differences. This overview summarizes existing knowledge on the BCRP transporter on molecular, tissue and system level, both in physiology and disease, and describes a selection of experimental procedures that are the most widely applied for the identification and characterization of substrate and inhibitor-type interactions.
引用
收藏
页码:1205 / 1248
页数:44
相关论文
共 490 条
[1]   Blood-brain barrier structure and function and the challenges for CNS drug delivery [J].
Abbott, N. Joan .
JOURNAL OF INHERITED METABOLIC DISEASE, 2013, 36 (03) :437-449
[2]   Transporting therapeutics across the blood-brain barrier [J].
Abbott, NJ ;
Romero, IA .
MOLECULAR MEDICINE TODAY, 1996, 2 (03) :106-113
[3]   Role of ABC Transporters in the Pathogenesis of Alzheimer's Disease [J].
Abuznait, Alaa H. ;
Kaddoumi, Amal .
ACS CHEMICAL NEUROSCIENCE, 2012, 3 (11) :820-831
[4]  
Adachi T, 2007, J EXP THER ONCOL, V6, P335
[5]   Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen [J].
Adachi, Y ;
Suzuki, H ;
Schinkel, AH ;
Sugiyama, Y .
MOLECULAR PHARMACOLOGY, 2005, 67 (03) :923-928
[6]   The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects [J].
Adkison, Kimberly K. ;
Vaidya, Soniya S. ;
Lee, Daniel Y. ;
Koo, Seok Hwee ;
Li, Linghui ;
Mehta, Amer A. ;
Gross, Annette S. ;
Polli, Joseph W. ;
Lou, Yu ;
Lee, Edmund J. D. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (02) :233-239
[7]   Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration [J].
Adkison, Kimberly K. ;
Vaidya, Soniya S. ;
Lee, Daniel Y. ;
Koo, Seok Hwee ;
Li, Linghui ;
Mehta, Amar A. ;
Gross, Annette S. ;
Polli, Joseph W. ;
Humphreys, Joan E. ;
Lou, Yu ;
Lee, Edmund J. D. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (02) :1046-1062
[8]   Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up [J].
Agarwal, Sagar ;
Hartz, Anika M. S. ;
Elmquist, William F. ;
Bauer, Bjoern .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (26) :2793-2802
[9]   The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain [J].
Agarwal, Sagar ;
Sane, Ramola ;
Ohlfest, John R. ;
Elmquist, William F. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 336 (01) :223-233
[10]   Flavonoid structure-activity studies identify 6-prenyichrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 [J].
Ahmed-Belkacem, A ;
Pozza, A ;
Muñoz-Martínez, F ;
Bates, SE ;
Castanys, S ;
Gamarro, F ;
Di Pietro, A ;
Pérez-Victoria, JM .
CANCER RESEARCH, 2005, 65 (11) :4852-4860